CompletedNot Applicable

Sugammadex Administration in Pregnancy

Turkey (Türkiye)26 participantsStarted 2023-03-15

Plain-language summary

In this study, the investigators aimed to evaluate the maternal and fetal effect of sugammadex in pregnant patients undergoing a non-obstetric surgery. The investigators mainly focused on the short- and long-term adverse effects such as an abortion or a teratogenic effect and that may occur in fetus and the adverse effects that may be seen in mother.

Who can participate

Age range18 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Pregnant women who were operated under general anesthesia during pregnancy and who used sugammadex during the awakening phase. Exclusion Criteria: * Patients with severe hepatic and renal impairment * Patients with missing data * Patients with fetal anomaly detected before the procedure

What they're measuring

Fetal outcome

Timeframe: one week postoperatively

Preterm labor

Timeframe: Labor that starts before 37 completed weeks of pregnancy

Trial details

NCT IDNCT05708469

SponsorSakarya University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-06-15

View on ClinicalTrials.gov More Sugammadex, Pregnant, Anesthesia trials